GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The company will respond to the US FDA within the stipulated timelines
The new centre brings advanced corneal procedures pioneered in India
The product will be marketed by Dr. Reddy's Laboratories Inc.
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Subscribe To Our Newsletter & Stay Updated
